Extrastriatal dopamine D 2 receptor binding in Huntington's disease

Human Brain Mapping

Volumn 32, Issue 10, 2011, Pages 1626-1636

  Esmaeilzadeh, Mouna ^a,b   Farde, Lars ^a,b   Karlsson, Per ^b   Varrone, Andrea ^a,b   Halldin, Christer ^b   Waters, Susanna ^c   Tedroff, Joakim ^b,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c NeuroSearch Sweden AB   (Sweden)

Author keywords

11C FLB 457; D 2 receptors; Dopamine; Huntington's disease; PET

Indexed keywords

DOPAMINE 2 RECEPTOR; ISOREMOXIPRIDE; ISOREMOXIPRIDE C 11; RADIOLIGAND; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; BRAIN SIZE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COGNITION; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; FEMALE; HUMAN; HUNTINGTON CHOREA; LIGAND BINDING; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RATING SCALE; RECEPTOR BINDING; SUBCORTEX; TASK PERFORMANCE; THALAMUS; UNIFIED HUNTINGTON DISEASE RATING SCALE; VOLUMETRY;

ADULT; AGED; BRAIN MAPPING; CARBON ISOTOPES; CORPUS STRIATUM; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; HUNTINGTON DISEASE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PYRROLIDINES; RECEPTORS, DOPAMINE D2; SALICYLAMIDES; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 80052670073     PISSN: 10659471     EISSN: 10970193     Source Type: Journal    
DOI: 10.1002/hbm.21134     Document Type: Article

References (56)

1. Aalto S, Bruck A, Laine M, Nagren K, Rinne JO (2005): Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: A positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. J Neurosci 25: 2471-2477.
2. Anderson KE, Marder KS (2001): An overview of psychiatric symptoms in Huntington's disease. Curr Psychiatry Rep 3: 379-388.
3. Andrews TC, Weeks RA, Turjanski N, Gunn RN, Watkins LH, Sahakian B, Hodges JR, Rosser AE, Wood NW, Brooks DJ (1999): Huntington's disease progression. PET and clinical observations. Brain 122: 2353-2363.
4. Backman L, Ginovart N, Dixon RA, Wahlin TB, Wahlin A, Halldin C, Farde L (2000): Age-related cognitive deficits mediated by changes in the striatal dopamine system. Am J Psychiatry 157: 635-637.
5. Benchoua A, Trioulier Y, Diguet E, Malgorn C, Gaillard MC, Dufour N, Elalouf J-M, Krajewski S, Hantraye P, Déglon N, Brouillet E (2008): Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II. Hum Mol Genet 17: 1446-1456.
6. Bergstrom M, Boethius J, Eriksson L, Greitz T, Ribbe T, Wideń L (1981): Head fixation device for reproducible position alignment in transmission CT and positron emission tomography. J Comput Assist Tomogr 5: 136-141.
7. Bonelli RM, Wenning GK (2006): Pharmacological management of Huntington's disease: An evidence-based review. Curr Pharm 12: 2701-2720.
8. Brandt J, Folstein SE, Wong DF, Links J, Dannals RF, McDonnell-Sill A, Starkstein S, Anders P, Strauss ME, Tune LE (1990): D2 receptors in Huntington's disease: Positron emission tomography findings and clinical correlates. J Neuropsychiatry Clin Neurosci 2: 20-27.
9. Christian BT, Lehrer DS, Shi B, Narayanan TK, Strohmeyer PS, Buchsbaum MS, Mantil JC (2006): Measuring dopamine neuromodulation in the thalamus: Using [F-18]fallypride PET to study dopamine release during a spatial attention task. Neuroimage 31: 139-152.
10. Clark M, Cramer RIII (1993): The probability of chance correlation using partial least squares (PLS). Quant Struct Act Relat 12: 137-145.
11. Craufurd D, Snowden J (2002): Neuropsychological and neuropsychiatric aspects of Huntington's disease. In: Bates G, Harper P, Jones L, editors. Huntington's Disease. New York: Oxford University Press. pp 62-69.
12. DiProspero NA, Chen EY, Charles V, Plomann M, Kordower JH, Tagle DA (2004): Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J Neurocytol 33: 517-533.
13. Eriksson L, Johansson E, Kettaneh-Wold N, Trygg J, Wikström C, Wold S (2006): Multi- and megavariate data analysis. PLS. In: Basic Principles and Applications. Umeå: Umetrics AB.
14. Farde L, Hall H, Pauli S, Halldin C (1995): Variability in D2-dopamine receptor density and affinity: A PET study with [11C]raclopride in man. Synapse 20: 200-208.
15. Farde L, Suhara T, Nyberg S, Karlsson P, Nakashima Y, Hietala J, Halldin C (1997): A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology (Berl) 133: 396-404.
16. Farde L, Pauli S, Hall H, Eriksson L, Halldin C, Hogberg T, Nilsson L, Sjogren I, Stone-Elander S (1998): Stereoselective binding of 11C-raclopride in living human brain-A search for extrastriatal central D2-dopamine receptors by PET. Psychopharmacology (Berl) 94: 471-478.
17. Feigin A, Tang C, Ma Y, Mattis P, Zgaljardic D, Guttman M, Paulsen JS, Dhawan V, Eidelberg D (2007): Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain 130: 2858-2867.
18. Folstein S (1989): Huntington's Disease: A Disorder of Families. Baltimore: Johns Hopkins University Press.
19. Gilbert AR, Rosenberg DR, Harenski K, Spencer S, Sweeney JA, Keshavan MS (2001): Thalamic volumes in patients with first-episode schizophrenia. Am J Psychiatry 158: 618-624.
20. Ginovart N, Lundin A, Farde L, Halldin C, Backman L, Swahn CG, Pauli S, Sedvall G (1997): PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 120: 503-514.
21. Gutekunst C, Norflus F, Hersch S (2002): The neuropathology of Huntington's disease. In: Bates G, Harper P, Jones L, editors. Huntington's Disease. New York: Oxford University Press. pp 251-275.
22. Hall H, Farde L, Halldin C, Hurd YL, Pauli S, Sedvall G (1996): Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [125I]epidepride. Synapse 23: 115-123.
23. Halldin C, Farde L, Hogberg T, Mohell N, Hall H, Suhara T, Karlsson P, Nakashima Y, Swahn C-G (1995): Carbon-11-FLB 457: A radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 36: 1275-1281.
24. Huntington Study Group (1996): Unified Huntington's disease rating scale: Reliability and consistency. Mov Disord 11: 136-142.
25. Jackson JE (1991): A user's guide to principle components. John Wiley and Sons, New York, p 592.
26. Kessler RM, Whetsell WO, Ansari MS, Votaw JR, de Paulis T, Clanton JA, Schmidt DE, Scott MN, Manning RG (1993): Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I]epidepride. Brain Res 609: 237-243.
27. Lammertsma AA, Hume SP (1996): Simplified reference tissue model for PET receptor studies. Neuroimage 4: 153-158.
28. Langer O, Halldin C, Dollé F, Swahn CG, Olsson H, Lundkvist P, Karlsson H, Hall J, Sandell C, Vaufrey F, Loch C, Crouzel C, Maziére B, Farde L (1999): Carbon-11 epidepride: A suitable radioligand for PET investigation of striatal and extrastriatal dopamine D2 receptors. Nucl Med Biol 26: 509-518.
29. Lawrence AD, Weeks RA, Brooks DJ, Andrews TC, Watkins LH, Harding AE, Robbins TW, Sahakian BJ (1998): The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. Brain 121: 1343-1355.
30. Maglione V, Cannella M, Martino T, Blasi A, Frati L, Squitieri F (2006): The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington's disease patients with predominant chorea. Neurosci Lett 393: 27-30.
31. Meltzer CC, Leal JP, Mayberg HS, Wagner HNJr, Frost JJ (1990): Correction of PET data for partial volume effects in human cerebral cortex by MR imaging. J Comput Assist Tomogr 14: 561-570.
32. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ (1984): A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 15: 217-227.
33. Modregger J, DiProspero NA, Charles V, Tagle DA, Plomann M (2002): PACSIN 1 interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains. Hum Mol Genet 11: 2547-2558.
34. Okauchi T, Suhara T, Maeda J, Kawabe K, Obayashi S, Suzuki K (2001): Effect of endogenous dopamine on extrastriated [11C]FLB 457 binding measured by PET. Synapse 41: 87-95.
35. Olsson H, Farde L (2001): Potentials and pitfalls using high affinity radioligands in PET and SPECT determinations on regional drug induced D2 receptor occupancy-A simulation study based on experimental data. Neuroimage 14: 936-945.
36. Pavese N, Andrews TC, Brooks DJ, Ho AK, Rosser AE, Barker RA, Robbins TW, Sahakian BJ, Dunnett SB, Piccini P (2003): Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease, a PET study. Brain 126: 1127-1135.
37. Pavese N, Politis M, Tai YF, Barker RA, Tabrizi SJ, Mason SL, Brooks DJ, Piccini P (2010): Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. Neurobiol Dis 37: 356-361.
38. Politis M, Pavese N, Tai YF, Tabrizi SJ, Barker RA, Piccini P (2008): Hypothalamic involvement in Huntington's disease: An in vivo PET study. Brain 131: 2860-2869.
39. Reading SAJ, Dziorny AC, Peroutka LA, Schreiber M, Gourley LM, Yallapragada V, Rosenblatt A, Margolis RL, Pekar JJ, Pearlson GD, Aylward E, Brandt J, Bassett SS, Ross CA (2004): Functional brain changes in presymptomatic Huntington's disease. Ann Neurol 55: 879-883.
40. Reisine TD, Fields JZ, Stern LZ, Johnson PC, Bird ED, Yamamura HI (1977): Alterations in dopaminergic receptors in Huntington's disease. Life Sci 21: 1123-1128.
41. Roland PE, Zilles K (1994): Brain atlases-A new research tool. Trends Neurosci 17: 458-467.
42. Rominger A, Wagner E, Mille E, Boning G, Esmaeilzadeh M, Wangler B, Gildehaus FJ, Nowak S, Bruche A, Tatsch K, Bartenstein P, Cumming P (2009): Endogenous competition against binding of [18F]DMFP and [18F]Fallypride to dopamine D2/3 receptors in brain of living mouse. Synapse 64: 313-322.
43. Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B (2005): Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 65: 745-747.
44. Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B, Greve D, Hevelone N, Hersch SM (2008): Cerebral cortex and the clinical expression of Huntington's disease: Complexity and heterogeneity. Brain 131: 1057-1068.
45. Strong TV, Tagle DA, Valdes JM, Elmer LW, Boehm K, Swaroop M, Kaatz KW, Collins FS, Albin RL (1993): Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat Genet 5: 259-265.
46. Suhara T, Sudo Y, Okauchi T, Maeda J, Kawabe K, Suzuki K, Okubo Y, Nakashima Y, Ito H, Tanada S, Halldin C, Farde L (1999): Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET. Int J Neuropsychopharmacol 2: 73-82.
47. Squitieri F, Gellera C, Cannella M, Mariotti C, Cislaghi G, Rubinsztein DC, Almqvist EW, Turner D, Bachoud-Levi A-C, Simpson SA, Delatycki M, Maglione V, Hayden MR, Donato S (2003): Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain 126: 946-955.
48. Tang TS, Chen X, Liu J, Bezprozvanny I (2007): Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J Neurosci 27: 7899-7910.
49. van Oostrom JC, Dekker M, Willemsen AT, de Jong BM, Roos RA, Leenders KL (2009): Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease. Eur J Neurol 16: 226-231.
50. van Vugt JP, van Hilten BJ, Roos RA (1996): Hypokinesia in Huntington's disease. Mov Disord 11: 384-388.
51. Varrone A, Sjoholm N, Eriksson L, Gulya's B, Halldin C, Farde L (2009): Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging 36: 1639-1650.
52. Volkow ND, Gur RC, Wang GJ, Fowler JS, Moberg PJ, Ding YS, Hitzemann R, Smith G, Logan J (1998): Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am J Psychiatry 155: 344-349.
53. Walker FO (2007): Huntington's disease. Semin Neurol 27: 143-150.
54. Weeks RA, Piccini P, Harding AE, Brooks DJ (1996): Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol 40: 49-54.
55. Wold S (1978): Cross-validatory estimation of the number of components in factor and principal component models. Tecnometrics 20: 397-405.
56. Young AB, Penney JB, Starosta-Rubinstein S, Markel DS, Berent S, Giordani B, Ehrenkaufer R, Jewett D, Hichwa R (1986): PET scan investigations of Huntington's disease, cerebral metabolic correlates of neurological features and functional decline. Ann Neurol 20: 296-230.